anlotinib + benmelstobart + nab-paclitaxel + gemcitabine

This is a combination regimen consisting of four agents: anlotinib, benmelstobart, nab-paclitaxel (albumin-bound paclitaxel), and gemcitabine. Anlotinib is a small molecule multi-targeted tyrosine kinase inhibitor with antiangiogenic and antitumor activity. Benmelstobart is a monoclonal antibody targeting PD-1 (programmed cell death protein 1), functioning as an immune checkpoint inhibitor. Nab-paclitaxel is a nanoparticle albumin-bound formulation of the microtubule inhibitor paclitaxel, while gemcitabine is a nucleoside analog that inhibits DNA synthesis. This combination has been investigated primarily for the first-line treatment of advanced or metastatic pancreatic adenocarcinoma, aiming to improve progression-free survival and overall survival compared to standard chemotherapy regimens[1][2][4]. The regimen leverages antiangiogenic therapy (anlotinib), immunotherapy (benmelstobart), and cytotoxic chemotherapy (nab-paclitaxel plus gemcitabine).

Other names

albumin-bound paclitaxel